您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > MMP-13 Inhibitor
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MMP-13 Inhibitor
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
MMP-13 Inhibitor图片
CAS NO:544678-85-5
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍

化学性质

Physical AppearanceA crystalline solid
StorageStore at -20°C
M.Wt410.4
Cas No.544678-85-5
FormulaC22H20F2N4O2
SynonymsCollagenase-3 Inhibitor,Matrix Metalloproteinase-13 Inhibitor,4,6-Pyrimidinedicarboxamide
Solubility≤0.5mg/ml in ethanol;2mg/ml in DMSO;2mg/ml in dimethyl formamide
Chemical NameN4,N6-bis[(4-fluoro-3-methylphenyl)methyl]-4,6-pyrimidinedicarboxamide
Canonical SMILESFC1=C(C)C=C(CNC(C2=CC(C(NCC3=CC=C(F)C(C)=C3)=O)=NC=N2)=O)C=C1
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

IC50: 8 nM

MMP-13 Inhibitor is a MMP-13 inhibitor.

Matrix metalloproteinases (MMPs), a family of zinc endopeptidases, can degrade proteins of the extracellular matrix, such as collagens, elastins, matrix glycoproteins, and proteoclycans. Zymogen activation and endogenous tissue inhibitors of matrix metalloproteinases control MMP activity during normal morphogenesis and tissue homeostasis. Abnormal expression or activity of MMPs has been reported to be related with pathological processes including metastasis, angiogenesis, cardiovascular disease, and rheumathoid arthritis and osteoarthritis.

In vitro: MMP-13 Inhibitor was previously synthesized as a pyrimidine dicarboxamide that could inhibit the matrix metalloproteinase-13 (MMP-13) with the IC50 of 8 nM. Moreover, MMP-13 Inhibitor was found to be able to bind to MMP pockets that are unique to MMP-13 rather than the catalytic zinc, and therefore was specific for MMP-13 over other MMPs. In addition, during endochondral ossification, MMP-13 Inhibitor could also block osterix-dependent calcification of matrices in limb bud cells [1, 2, 3].

In vivo: So far, there is no animal in vivo study reported.

Clinical trial: So far, no clinical study has been conducted.

References:
1.  Carrascal, N.A. and Rizzo, R.C. Calculation of binding free energies for non-zinc chelating pyrimidine dicarboxamide inhibitors with MMP-13. Bioorg.Med.Chem.Lett. 19(1), (2009).
2.  Engel, C.K.,Pirard, B.,Schimanski, S., et al. Structural basis for the highly selective inhibition of MMP-13. Chem.Biol. 12(2), 181-189 (2005).
3.  Nishimura, R.,Wakabayashi, M.,Hata, K., et al. Osterix regulates calcification and degradation of chondrogenic matrices through matrix metalloproteinase 13 (MMP13) expression in association with transcription factor Runx2 during endochondral ossification. J.Biol.Chem. 287(40), 33179-33190 (2012).